|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
8/13/2012 9:49:49 AM
QUÉBEC CITY, Aug. 13, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the "Company") today announced that its V.P.,
Medicinal Chemistry, Matthias Gerlach, PhD, will be making a poster
presentation on preclinical results for the Company's novel orally
active anticancer PI3K/Erk 1/2 inhibitor, AEZS-136, during the 244th National Meeting of the American Chemistry Society which will be held
August 19-23, 2012, in Philadelphia.
| Poster #46:
|
|
"Dual PI3K/Erk Inhibitor AEZS-136, A Potent Anti-Tumor Compound
Under Preclinical Development ", M. Gerlach, I. Seipelt, L. Blumenstein, K. Jung, T. Schuster, G.
Mueller, E. Guenther, J. Engel and M. Teifel. | |
|
|
| | Session: |
|
General poster session / division of medicinal chemistry;
| Dates and time:
|
|
Sunday, August 19, 2012 from 7pm to 9pm (Eastern); and
Monday, August 20, 2012 from 8pm to 10pm (Eastern);
| | Venue: |
|
Pennsylvania Convention Center, Hall D
|
About AEZS-136
AEZS-136 is an integral part of the Company's kinase research program
comprising the investigation of different compounds for single Erk
inhibition, single PI3K inhibition and dual Erk/PI3K kinase inhibition.
AEZS-136 selectively inhibits the kinase activity of Erk 1/2 and class
1 PI3Ks, enabling simultaneous inhibition of the Raf-Mek-Erk and the
PI3K-Akt signaling cascades. AEZS-136 was discovered using the
Company's proprietary compound library and high throughput screening
technology.
About Aeterna Zentaris
Aeterna Zentaris is an oncology and endocrinology drug development
company currently investigating treatments for various unmet medical
needs. The Company's pipeline encompasses compounds at all stages of
development, from drug discovery through to marketed products. For more
information please visit www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.
|
|
|
|
|
|
|
|
|
|
|